PATENT CLAIM ANALYSIS

Application Number: 15994502
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-03
Patent Classification: ["514", "183000"]

Abstract:
The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

Claim (Index 30):
The composition of  claim 12  wherein the composition comprises bisantrene and is formulated for use to employ a novel mechanism of action in its therapeutic activity wherein the novel mechanism of action is a therapeutic interaction with a target or mechanism selected from the group consisting of:\n (a) inhibitors of poly-ADP ribose polymerase; \n (b) agents that affect vasculature; \n (c) agents that promote vasodilation; \n (d) oncogenic targeted agents; \n (e) signal transduction inhibitors; \n (f) agents inducing EGFR inhibition; \n (g) agents inducing Protein Kinase C inhibition; \n (h) agents inducing Phospholipase C downregulation; \n (i) agents including jun downregulation; \n (j) agents modulating expression of histone genes; \n (k) agents modulating expression of VEGF; \n (l) agents modulating expression of ornithine decarboxylase; \n (m) agents modulating expression of jun D; \n (n) agents modulating expression of v-jun; \n (o) agents modulating expression of GPCRs; \n (p) agents modulating expression of protein kinase A; \n (q) agents modulating expression of protein kinases other than protein kinase A; \n (r) agents modulating expression of telomerase; \n (s) agents modulating expression of prostate specific genes; \n (t) agents modulating expression of histone deacetylase; \n (u) agents modulating expression of a checkpoint regulator selected from the group consisting of CTLA-4, PD-1, PD-2, and OX-40; and \n (v) agents modulating expression of a molecule selected from mTOR, Akt3m and PI3K.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 93.0
- Lexical Diversity: 1.31579
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15979041', '14907728', '14907729', '13817096', '14250958']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8178195247934666
- 35 USC 102 Novelty (BERT): 0.5309536540342217
- Combined Prediction Score: 0.7891329377175422
- Mean Citation Score: 276.52593
- Max Citation Score: 362.98706
- Similarity Product: 248.3129685936952

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test